-The Telegraph   New Delhi: The Supreme Court today asked the Centre to allow clinical trials on new pharmaceutical compounds only after ensuring to the extent possible that their potential benefits outweigh their risks and they are needed in India. A bench of Justices R.M. Lodha and Kurien Joseph, responding to a public interest petition by a non-government organisation called Swasthya Adhikar Manch, also told the Centre to ensure that the candidate compounds...

-The Times of India Funding for one of the foremost drug discovery projects in India came to an end on Monday as the financial year closed because the ministry of science and technology did not clear the cabinet note meant to extend funding for the project on time. The Open Source Drug Discovery (OSDD) project of the Council of Scientific and Industrial Research (CSIR), meant to discover drugs for neglected diseases, had...

-The Hindu In the case of technologies with benefits and risks, it is important to have regulatory mechanisms which can help analyse them in an impartial manner It is 61 years since the beginning of new genetics based on the discovery of the double helix structure of the DNA molecule. It is also 31 years since the production of transgenic plants. The first patent for a living organism went to Dr. Anand...

-The Times of India NEW DELHI: The new draft protocol for clinical trials of drugs, on the lines suggested by the Supreme Court, is making it difficult for global drug manufacturers to find subjects for testing new chemical compositions. The protocol has made it mandatory for companies intending to conduct human trials of drugs to video-record the free consent of patients to be part of the trial. It also mandates them to...

-The Hindu Unless a deeper, institutional change is ushered in to break the nexus between drug companies and the regulatory regime, Indians consuming drugs may be exposing themselves to serious risks Even before I walked into the Mayflower Hotel in the heart of Washington on a crisp autumn afternoon to meet Dinesh Thakur, whistle-blower and former director of India-based pharmaceutical giant Ranbaxy, I had a hunch that this conversation would spark some...